Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 7/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30989956 | 0.90 | MAPK1 (0.54) | MAPK1P2RX7HTR2A | |
| SCHEMBL30989846 | 0.88 | GPR6 (0.42) | P2RX7RIPK1MALT1CRHR1 | |
| SCHEMBL30990021 | 0.81 | TAS1R3 (0.57) | — | |
| SCHEMBL30989814 | 0.79 | MAPK1 (0.36) | MAPK1MALT1 | |
| SCHEMBL30989892 | 0.78 | NTRK1 (0.46) | MAPK1P2RX7CRHR1 | |
| SCHEMBL30989860 | 0.78 | NTRK1 (0.39) | P2RX7RIPK1 | |
| SCHEMBL30989858 | 0.78 | GPR6 (0.39) | P2RX7RIPK1MALT1 | |
| SCHEMBL30989933 | 0.77 | P2RX7 (0.42) | MAPK1P2RX7CRHR1 | |
| SCHEMBL30989929 | 0.77 | P2RX7 (0.42) | MAPK1P2RX7CRHR1 | |
| SCHEMBL30989984 | 0.71 | PTGER4 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |